Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Franke

Showing results (581-590 of 593) with videos related to

Pageof 60
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Plos One|July 30, 2021
Genome-wide association study of pancreatic fat: The Multiethnic Cohort Adiposity Phenotype StudySamantha A Streicher, Unhee Lim, S Lani Park, et al.
Journal of Dental Research|January 3, 2018
Integration of Murine and Human Studies for Mapping Periodontitis SusceptibilityA Nashef, R Qabaja, Y Salaymeh, et al.
Journal of the National Cancer Institute|December 11, 2012
Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studiesA Heather Eliassen, Sara J Hendrickson, Louise A Brinton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)Fernando C Maluf, Fabio A Schutz, Eduardo H Cronemberger, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
British Journal of Cancer|April 11, 2013
Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222V Enciso-Mora, F J Hosking, A L Di Stefano, et al.
HLA|July 12, 2017
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestryE K K Henriksen, M K Viken, M Wittig, et al.
Nature Food|April 28, 2023
Climate impacts on global agriculture emerge earlier in new generation of climate and crop modelsJonas Jägermeyr, Christoph Müller, Alex C Ruane, et al.
Pageof 60

Showing results (581-590 of 593) with videos related to

Sort By:
Pageof 60
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate CancerTomasz M Beer, Eugene D Kwon, Charles G Drake, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Plos One|July 30, 2021
Genome-wide association study of pancreatic fat: The Multiethnic Cohort Adiposity Phenotype StudySamantha A Streicher, Unhee Lim, S Lani Park, et al.
Journal of Dental Research|January 3, 2018
Integration of Murine and Human Studies for Mapping Periodontitis SusceptibilityA Nashef, R Qabaja, Y Salaymeh, et al.
Journal of the National Cancer Institute|December 11, 2012
Circulating carotenoids and risk of breast cancer: pooled analysis of eight prospective studiesA Heather Eliassen, Sara J Hendrickson, Louise A Brinton, et al.
European Journal of Cancer (Oxford, England : 1990)|October 16, 2021
A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)Fernando C Maluf, Fabio A Schutz, Eduardo H Cronemberger, et al.
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
British Journal of Cancer|April 11, 2013
Low penetrance susceptibility to glioma is caused by the TP53 variant rs78378222V Enciso-Mora, F J Hosking, A L Di Stefano, et al.
HLA|July 12, 2017
HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestryE K K Henriksen, M K Viken, M Wittig, et al.
Nature Food|April 28, 2023
Climate impacts on global agriculture emerge earlier in new generation of climate and crop modelsJonas Jägermeyr, Christoph Müller, Alex C Ruane, et al.
Pageof 60